Abstract: A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer.

Abstract: A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer.

Abstract: A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer.

Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.

Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.

Abstract: Methods of administering probiotic bacteria to livestock animals in an amount effective to reduce the amount of hazardous bacteria. Probiotic bacteria in an acceptable carrier are administered to the livestock at a selected time before transportation of the animal for harvest or other purposes. The invention also provides compositions comprising probiotic bacteria in an amount effective to reduce the amount of Salmonella in livestock animals.

Abstract: The invention provides compositions comprising Felix 0-1 Phage (F01 phage) in a an-acceptable carrier and methods of administering the compositions to a livestock animal to reduce or prevent dissemination of Salmonella.

Abstract: The invention provides compositions comprising Felix 0-1 Phage (F01 phage) in a an-acceptable carrier and methods of administering the compositions to a livestock animal to reduce or prevent dissemination of Salmonella.

Abstract: The resistance of swine to dysentery infection is increased by the combined parenteral and oral administration of killed cells of Treponema hyodysenteriae (T. hyo.). A sensitizing parenteral dose of the T. hyo. is administered first and, after delay of a number of days, the swine are given a feed containing the killed T. hyo. cells adsorbed on a porous carrier. The method is particularly applicable for the protection of young, growing pigs against swine dysentery infection.

Abstract: A combination vaccine for increasing the resistance of swine to dysentery infection comprises killed cells of a virulent isolate of Treponema hyodysenteriae in combination with concentrated killed cells of Bacteroides vulgatus, or Fusobacterium necrophorum, or mixtures thereof. This combination vaccine can be adapted for either oral or parenteral administration. For parenteral administration preferably only Bacteroides vulgatus is used in combination with Treponema hyodysenteriae. The oral vaccine is enteric-coated.

Abstract: A combination vaccine for increasing the resistance of swine to dysentery infection comprises killed cells of a virulent isolate of Treponema hyodysenteriae in combination with concentrated killed cells of Bacteroides vulgatus, or Fusobacterium necrophorum, or mixtures thereof. This combination vaccine can be adapted for either oral or parenteral administration. For parenteral administration preferably only Bacteroides vulgatus is used in combination with Treponema hyodysenteriae. The oral vaccine is enteric-coated.

Abstract: The resistance of field-raised swine to dysentery infection is increased by a sequence of parenteral and oral administrations. First there is parenterally administered to the swine an injectable cell concentrate containing a virulent isolate of killed cells of Treponema hyodysenteriae, and not less than five days after the animals have received the first of the parenteral injections, a series of oral administrations of enteric-coated pellets is started, the pellets containing concentrated killed cells of a virulent isolate of T. hyodysenteriae. The oral administrations are given at least once every 24 hours for a period of at least five days.

Abstract: The resistance of swine to swine dysentery infection is increased by parenteral administration of killed cells of a virulent isolate of Treponema hyodysenteriae.